Aczone

Aczone is a brand name of dapsone topical, approved by the FDA in the following formulation(s):

ACZONE (dapsone - gel; topical)

• 
  Manufacturer: ALLERGAN
  
  Approval date: July 7, 2005
  
  Strength(s): 5% ^[RLD]

Has a generic version of Aczone been approved?

No. There is currently no therapeutically equivalent version of Aczone available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Aczone. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Compositions and methods for topical application of therapeutic agents
  Patent 5,863,560
  Issued: January 26, 1999
  Inventor(s): Osborne; David W.
  Assignee(s): ViroTex Corporation
  The present invention generally relates to pharmaceutical compositions that enable control of drug delivery properties and the development of optimal drug delivery strategies customized for particular drugs and particular diseases. The composition includes a dissolved pharmaceutical that has the capacity to permeate the stratum corneum layer of the epidermis and become available systemically, and a pharmaceutical in a microparticulate state that does not readily cross the stratum corneum of the epidermis. The dissolved and microparticulate pharmaceuticals may be the same or different pharmaceuticals. Methods for the preparation and use of the compositions are also provided. In a preferred embodiment, the invention finds particular use in a formulation for the topical application of dapsone for the treatment of acne. In another preferred embodiment, the invention finds particular use for the treatment of herpes lesions.
  
  Patent expiration dates:
  
  
  • September 11, 2016
    
    ✓ 
    Drug product
  
  



• 
  Compositions and methods for topical application of therapeutic agents
  Patent 6,060,085
  Issued: May 9, 2000
  Inventor(s): Osborne; David W.
  The present invention generally relates to pharmaceutical compositions that enable control of drug delivery properties and the development of optimal drug delivery strategies customized for particular drugs and particular diseases. The composition includes a dissolved pharmaceutical that has the capacity to permeate the stratum corneum layer of the epidermis and become available systemically, and a pharmaceutical in a microparticulate state that does not readily cross the stratum corneum of the epidermis. The dissolved and microparticulate pharmaceuticals may be the same or different pharmaceuticals. Methods for the preparation and use of the compositions are also provided. In a preferred embodiment, the invention finds particular use in a formulation for the topical application of dapsone for the treatment of acne. In another preferred embodiment, the invention finds particular use for the treatment of herpes lesions.
  
  Patent expiration dates:
  
  
  • September 11, 2016
    
    ✓ 
    Patent use: TREATMENT OF ACNE
  
  



• 
  Compositions for topical application of therapeutic agents
  Patent 6,620,435
  Issued: September 16, 2003
  Inventor(s): David W.; Osborne
  Assignee(s): ViroTex Corporation
  The present invention generally relates to pharmaceutical compositions that enable control of drug, delivery properties and the development of optimal drug delivery strategies customized for particular drugs and particular diseases. The composition includes a dissolved pharmaceutical that has the capacity to permeate the stratum corneum layer of the epidermis and become available systemically, and a pharmaceutical in a microparticulate state that does not readily cross the stratum corneum of the epidermis. The dissolved and microparticulate pharmaceuticals may be the same or different pharmaceuticals. Methods for the preparation and use of the compositions are also provided. In a preferred embodiment, the invention finds particular use in a formulation for the topical application of dapsone for the treatment of acne. In another preferred embodiment, the invention finds particular use for the treatment of herpes lesions.
  
  Patent expiration dates:
  
  
  • September 11, 2016
    
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • March 14, 2011 - REMOVAL OF SCREEN REQUIREMENT IN PTS WITH G6PD DEFICIENCY PRIOR TO INITIATING ACZONE TREATMENT; REMOVAL OF BLOOD COUNT & RETICULOCYTE MONITORING DURING TREATMENT IN G6PD DEFICIENT PTS AND IN PATIENTS WITH HISTORY OF ANEMIA
  
  

See also...

• Aczone Consumer Information (Drugs.com)
• Aczone Gel Consumer Information (Wolters Kluwer)
• Aczone Consumer Information (Cerner Multum)
• Aczone Topical Advanced Consumer Information (Micromedex)
• Aczone topical AHFS DI Monographs (ASHP)
• Dapsone Gel Consumer Information (Wolters Kluwer)
• Dapsone topical Consumer Information (Cerner Multum)
• Dapsone Topical Advanced Consumer Information (Micromedex)
• Dapsone topical AHFS DI Monographs (ASHP)